GCGR and metabolic dysfunction-associated steatotic liver disease: DD01, a long-acting dual agonist for GLP-1R/GCGR, is also in a phase 1 clinical trial to investigate the effects on NASH, T2DM, and obesity (A Phase 1 Study of DD01 in Overweight/Obese Subjects with T2DM and NAFLD, NCT04812262, phase 1).